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Infectious diseases are a major global concern and despite major advancements in
medical research, still cause significant morbidity and mortality. Progress in antiviral
therapy is particularly hindered by appearance of mutants capable of overcoming the
effects of drugs targeting viral components. Alternatively, development of drugs targeting
host proteins essential for completion of viral lifecycle holds potential as a viable strategy
for antiviral therapy. Nucleocytoplasmic trafficking pathways in particular are involved
in several pathological conditions including cancer and viral infections, where hijacking
or alteration of function of key transporter proteins, such as Chromosome Region
Maintenance1 (CRM1) is observed. Overexpression of CRM1-mediated nuclear export
is evident in several solid and hematological malignancies. Interestingly, CRM1-mediated
nuclear export of viral components is crucial in various stages of the viral lifecycle and
assembly. This review summarizes the role of CRM1 in cancer and selected viruses.
Leptomycin B (LMB) is the prototypical inhibitor of CRM1 potent against various cancer
cell lines overexpressing CRM1 and in limiting viral infections at nanomolar concentrations
in vitro. However, the irreversible shutdown of nuclear export results in high cytotoxicity
and limited efficacy in vivo. This has prompted search for synthetic and natural CRM1
inhibitors that can potentially be developed as broadly active antivirals, some of which
are summarized in this review.
Keywords: CRM1, CRM1 inhibitors, CRM1-mediated nuclear export, CRM1 in cancer, CRM1-mediated export of
viral proteins
INTRODUCTION
Overview
Despite concerted effort, spearheaded by the World Health Organization (WHO), the number of
deaths caused by infectious diseases is falling slowly. In 1990, an estimated 13 million people died
from communicable diseases, including viral, bacterial, parasitic and nematode infections. There
has been only a marginal drop in number of deaths from infectious disease in 2015 and is forecast
to be around 13 million even in 2030 (WHO, 2011). Clearly, there remains a need for continuing
drug development.
A major stumbling block in antiviral therapy is the emergence of escape mutants that frequently
follows strategies that target viral components (Endy and Yin, 2000). A better, more effective,
strategy would be to target an essential host protein that is exploited by diverse viruses; however,
this has the associated risk of high cytotoxicity. The challenge is to develop a drug that is effective
against numerous viruses, including emerging and re-emerging viruses, with minimal cytotoxicity
(Hung and Link, 2011; Bekerman and Einav, 2015).
Regulated, appropriate translocation and subcellular localization of proteins is essential for
regulation of replication, transcription, and translation (Weis, 2003). Dysregulation of this system
Mathew and Ghildyal CRM1 Inhibitors for Antiviral Therapy
is observed in several pathological conditions including cancer
and viral infections (Weis, 2003; Hung and Link, 2011; Le
Sage and Mouland, 2013). Chromosome Region Maintenance1
(CRM1), a nuclear transporter protein, mediates the export of
around 220 proteins and mRNA across the nuclear envelope
(NE), and is involved in regulation of processes involved with
proliferation including cell cycle progression and apoptosis (Xu
et al., 2012). CRM1 is a key protein overexpressed in several
solid and hematological malignancies where mislocalization of
tumor suppressor proteins promotes malignancy and tumor
progression (Hung and Link, 2011). CRM1 is also utilized by
viruses at various stages of their lifecycle to mislocalize cellular
proteins as well as ensure appropriate localization of viral
proteins (Le Sage and Mouland, 2013). Given that viruses of
diverse families, e.g., retroviruses, DNA and RNA viruses exploit
or modulate CRM1-mediated nuclear export, effective targeting
of CRM1 would lead to a broadly effective drug potentially active
against current and future virus infections.
NUCLEOCYTOPLASMIC TRANSPORT
Spatial partition of the nucleoplasm from the cytoplasm by
the NE in the eukaryotic cell allows cellular functions to
be restricted to specialized organelles and enables a multi-
layered functional regulation of fundamental cellular processes,
such as DNA synthesis, RNA transcription/transport, protein
translation/maturation, cell division and signal transduction
(reviewed in Weis, 2003; Talamas and Capelson, 2015). The
double membrane structure of the NE contains numerous
nuclear pore complexes (NPC) that are the only conduit
of macromolecular trafficking between the nucleus and the
cytoplasm. Consisting of a central core structure with nuclear and
cytoplasmic extensions, the NPC is a highly selective molecular
sieve that regulates bidirectional transport of macromolecules
larger than 60 kDa (Mattaj and Englmeier, 1998; Gorlich and
Kutay, 1999). Although passive flux of molecules <55 kDa can
occur, most transport through the NPC is mediated by members
of the karyopherin superfamily, which recognize nuclear
localization sequences (NLSs) or nuclear export sequences
(NESs) on cargo molecules for transport into and out of the
nucleus, respectively. Shuttling transport receptors mediate all
cargo transport and operate via similar mechanisms. Initiated by
the recognition of the signaling motifs (NLS or NES) on cargo
molecules, the shuttling transport receptors, such as importins
and exportins, carry out nucleocytoplasmic exchange from
the originating compartment to the target destination. Upon
delivery, the empty receptors cycle back to mediate additional
rounds of transport (Gorlich and Mattaj, 1996; Mattaj and
Englmeier, 1998; Khmelinskii et al., 2014).
Nuclear Import
Nuclear import includes sequential docking/undocking events
between the cargo/importin complex and the membrane-
imbedded NPC, followed by the disassociation of the complex
in the nucleoplasm, where the binding of RanGTP to importin
releases it from the transport complex (Gorlich and Mattaj, 1996;
Macara, 2001; Terry et al., 2007; Chumakov and Prassolov, 2010).
Nuclear Export
Nuclear export is essentially the same as nuclear import,
in the opposite direction; with the main difference that
RanGTP is an integral component of the complex in nuclear
export, transporting the cargo/exportin from the nucleus to
the cytoplasm (Figure 1). One of the most well characterized
exportins is (CRM1; also, referred to as Exportin1 or XPO1).
CRM1 binds to cargoes in the nucleus in the presence of
RanGTP via a NES composed of a cluster of leucine (L)-rich or
hydrophobic amino acids. After transit the hydrolysis of Ran-
GTP by RanGAP (a GTPase) disassembles the trimeric complex
and CRM1 re-enters the nucleus (Figure 1; Gorlich and Mattaj,
1996; Macara, 2001; Hutten and Kehlenbach, 2007; Chumakov
and Prassolov, 2010; Xu et al., 2012).
CRM1
Chromosome Region Maintenance1 (CRM1) architecture is
conserved across species including humans, mice, fungi and
yeast (Fung and Chook, 2014). CRM1 is a 120 kDa ring-shaped
karyopherin protein composed of 21 tandem HEAT repeats,
designated H1-H21, containing a pair of anti-parallel helices A
and B that form the outer convex and inner concave surfaces
(Dickmanns et al., 2015). The NES-binding groove on the surface
of CRM1 is located between H11 and H12. CRM1 binds to
protein cargoes at its outer convex surface by anchoring to
key hydrophobic residues in the NES peptide into the NES-
binding groove, unlike importins which bind with residues on
their inner surface. Conformational changes involving H21 and
H9 loop (a long conserved loop that connects H9A and H9B)
are key structural elements crucial for CRM1 function. CRM1
adopts a ring-shaped structure with its N- and C-terminal HEAT
repeats in close proximity which compacts further on forming a
complex with the cargo and Ran GTP. In the unliganded state
the H9 loop, which connects H9A and H9B, brings the helices
H11A and H12A closer to each other and cuts off access to the
NES groove. In addition, H21 crosses the CRM1 ring, interacts
with both the H9 loop and the NES binding groove to render
CRM1 inactive. In the CRM1-cargo-Ran GTP complex, H21
aligns itself with the CRM1 ring and the H9 loop adopts a beta-
hairpin structure which displaces it from theNES binding groove.
These conformational changes are crucial for the functioning
of CRM1 whereby it adopts three conformations including an
inactive ligand-free state with a closed NES groove, an active
NES and RanGTP-bound state with an open groove and an
intermediate NES bound (without RanGTP) state. The cysteine
residue located within the hydrophobic NES-binding region at
position 528 is the prime target for most CRM1 inhibitors
including leptomycin B (LMB) (Petosa et al., 2004; Monecke
et al., 2009; Sun et al., 2013; Fung and Chook, 2014; Turner et al.,
2014).
Functions
Among the seven known nuclear export proteins in the
Karyopherin family, CRM1 is the best characterized nuclear
exporter. CRM1 is the sole nuclear exporter of several cellular
growth and survival factors including proteins and RNA.
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FIGURE 1 | Nuclear export. Nuclear export is initiated by the recognition of an NES-carrying cargo by CRM1 and formation of a tricomplex with RanGTP. This is
followed by sequential docking and undocking events at the NPC. After translocation into the cytoplasm the tricomplex is dissociated by the hydrolysis of RanGTP to
RanGDP by RanGAP. The released CRM1 protein returns to the nucleus and repeats the process.
CRM1-mediated transport mediates cell proliferation through
several pathways (Figure 2). (i) The subcellular localization
of NES-containing oncogenes and tumor suppressor proteins
involved in regulating cell division, controlling apoptotic
pathways, and maintain genomic integrity by recognizing and
repairing DNA damage. Many of these regulatory proteins
are mislocalized in a large variety of tumors (Turner et al.,
2014; Sun et al., 2016). (ii) The control of mitotic apparatus
and chromosome segregation through the regulated export
of centrosome-associated proteins. For instance, inhibition
of nucelophosmin by LMB results in its dissociation from
centrosomes and premature centrosome duplication (Wang
et al., 2005). BRCA1, a tumor suppressor protein commonly
mutated in breast and ovarian cancer, stimulates DNA repair
at the nucleus and inhibits centrosomal duplication in response
to DNA damage (Arnaoutov et al., 2005; Nguyen et al., 2012).
Disruption of CRM1-mediated export blocks the localization
of BRCA1 at the centrosome and results in failure for cells to
detect DNA damage (Brodie and Henderson, 2012). (iii) crm1
yeast mutants had altered chromosomal structures that appeared
as rod-like thickened fibers suggesting a role for CRM1 in
maintenance of chromosomal and nuclear structures (Toda et al.,
1992). In addition, abnormal nuclear morphology and cell cycle
arrest at both G1 and G2 phases were observed in leptomycin-
treated yeast (Nishi et al., 1994). CRM1 levels remain constant
throughout the cell cycle and it is mainly localized to the NE
in highly specialized cellular bodies called CRM1 nuclear bodies
(CNoBs) that depend on RNA polymerase1 activity, suggesting a
role in ribosome biogenesis (Gravina et al., 2014).
The structure and functions of CRM1 are dealt with in detail
in several excellent reviews and will not be discussed further in
this review.
CRM1 IN CANCER
Shuttling regulatory proteins into and out of the nucleus is
essential for regulation of cell cycle and proliferation. Cancer
cells utilize nucleocytoplasmic trafficking pathways to stimulate
tumor growth and to evade apoptosis (Gravina et al., 2014).
There are numerous studies showing that protein up-regulation,
or RNA/DNA amplification of importin and/or CRM1, correlates
with neoplasia and poor prognosis (Senapedis et al., 2014).
CRM1 is the sole nuclear exporter of several tumor supressor
proteins and growth regulatory proteins including p53, p21, p73,
Rb1, Adenomatous polyposis coli (APC), BCR-ABL, FOXO, and
STAT3 (Parikh et al., 2014; Turner et al., 2014; Sun et al., 2016).
Nuclear export of tumor suppressor proteins in normal cells
prevents them from interacting with transcription factors in the
absence of DNA damage or oncogenic stimuli (Parikh et al.,
2014).
Overexpression of CRM1 is observed in solid and hematologic
malignancies (Turner and Sullivan, 2008; Parikh et al., 2014; Das
et al., 2015). Overexpression of CRM1 results in mislocalization
of regulatory factors away from their original site of action in
the nucleus and disrupts DNA topology, tumor suppression,
cell cycle, and apoptosis (Turner et al., 2012a). This promotes
malignancy, evasion of apoptosis and immune detection, and
develops drug resistance.
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FIGURE 2 | Function of CRM1-mediated export and its significance in cancer. The illustration summarizes some of the key proteins, including tumor suppressor
proteins, cell cycle regulators, mediators of cell proliferation and apoptosis, proteins involved in maintenance of chromosomal and nuclear structures and others,
regulated by CRM1-mediated nuclear export and their role in several solid and/or hematological malignancies. Abbreviations. APC, Adenomatous Polyposis Coli;
ATF2, Activating transcription factor 2; BCR-ABL, Breakpoint Cluster Region/Abelson murine leukemia viral oncogene homolog 1 Bok, Bcl-2 related ovarian killer;
BRCA1-Early Onset Breast Cancer 1; CIP2A, Cancerous Inhibitor of PP2A; ERα, Estrogen Receptor; ERK, Extracellular signal-Regulated Kinases; FOXO, Forkhead
family of transcription factors; HMGB1, High Mobility Group Box 1; Hsp90, Heat Shock Protein 90; RASSF2, Ras association (RalGDS/AF-6) domain family member
2; RB, Retinoblastoma; RUNX3, Runt-related transcription factor 3; Tob, Transducer of ErbB-2.
Mutations in tumor suppressor proteins also result in
mislocalization as it disrupts its ability to bind to CRM1 and
exit the nucleus for proteosomal degradation. Overexpression of
CRM1 in cervical cancer cell lines reduced the nuclear retention
of several tumor suppressors including p53, p27, p21, and p18.
siRNA-induced inhibition of CRM1 in cervical cancer cell lines
significantly reduced proliferation and promoted cell death, while
non-cancer cells remained unaffected (van der Watt et al., 2009).
Mutations in some cancer-associated proteins produce
truncated products lacking NES or with reduced capability to
bind to CRM1, resulting in increased nuclear retention (Lu et al.,
2015). For instance, APC is a tumor suppressor protein that
regulates β-catenin, a major component of the Wnt signaling
pathway, and suppresses tumor progression. In a normal cell,
APC chaperones β-catenin and promotes its CRM1-mediated
export into the cytoplasm where β-catenin level is regulated
by degradation. Mutations in APC gene cause malignant colon
cancer and the intestinal polyp disorder familial adenomatous
polyposis (Powell et al., 1992). The mutated APC accumulates in
the nucleus, becomes less efficient in binding to β-catenin and
retards CRM1-mediated export thereby promoting oncogenic
cellular transformation (Powell et al., 1992; Henderson, 2000).
Chromosome Region Maintenance1 (CRM1) is therefore a
promising cancer drug target, and the use of small molecule
inhibitors of CRM1 for a variety of cancers has been reviewed
in detail (Turner et al., 2012a, 2014; Gravina et al., 2014; Parikh
et al., 2014; Senapedis et al., 2014; Tan et al., 2014; Das et al., 2015)
and will not be discussed further.
CRM1 IN VIRAL INFECTIONS
Chromosome Region Maintenance1 (CRM1) has a key role
in viruses from diverse families, including retroviruses,
orthomyxoviruses, paramyxoviruses, flaviviruses, coronaviruses,
rhabdoviruses, and herpesviruses. CRM1-mediated export is co-
opted by many viruses during various stages of the viral lifecycle.
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Interruption of CRM1-mediated export results in changes in
virion protein expression, virion replication, incomplete viral
assembly, reduced infectivity, and improved antiviral host
immune responses (Elton et al., 2001; Pasdeloup et al., 2005; Cao
and Liu, 2007; Sanchez et al., 2007; Ghildyal et al., 2009; Cao
et al., 2012; Liu et al., 2012; Nakano and Watanabe, 2016). In the
following sections, we review the utilization of CRM1 and its role
in the lifecycle of representative viruses from selected families.
Human Immunodeficiency Virus Type 1
(HIV-1)
A member of the family Retroviridae, HIV-1 encodes nine genes
arranged as a series of 12 alternatively spliced exons (Kimura
et al., 1996). Retroviral replication requires translation of fully
spliced mRNA encoding Tat, Rev, and Nef proteins early in
infection followed by cytoplasmic expression of a set of late-
phase unspliced or partly spliced mRNAs encoding structural
and accessory proteins (Kimura et al., 1996; Najera et al., 1999).
HIV Rev protein is a 19 kDa phosphoprotein that mediates
controlled expression of 4 and 9 kb retroviral mRNAs (encoding
the vif, vpr, and vpu/env genes and the gag/pol gene, respectively)
in the nucleus (Najera et al., 1999; Fontoura et al., 2005). Rev
protein carries an NLS peptide enabling translocation into the
nucleus, an RRE-binding (Rev response element) domain that
binds to the unspliced mRNA, as well as an “activation” domain
which contains the NES peptide which allows shuttling of the
transcripts into the cytoplasm using CRM1-mediated export
(Table 1; Kimura et al., 1996;Wolff et al., 1997; Najera et al., 1999;
Urcuqui-Inchima et al., 2011). The binding of Rev to unspliced
transcripts carrying the RRE creates an RNP filament with the
NES displayed on the surface and provides a transient “tag” which
directs to CRM1 (Najera et al., 1999).
HIV-1 Rev is an indispensable regulatory factor for virion
protein expression (Cao and Liu, 2007). The unspliced and
partially spliced mRNA will be degraded in the absence of
Rev, resulting in interruption of HIV-1 replication at the same
time (Cao and Liu, 2007). CRM1-assisted export of gag mRNA
enables efficient processing of Gag proteins and production
of viral particles (Nagai-Fukataki et al., 2011). Disruption of
the Rev RRE-CRM1 complex and inhibition of CRM1/Rev-
mediated viral RNA transport using CRM1 inhibitors, such as
LMB, ratjadone A (Fleta-Soriano et al., 2014), and a synthetic
low molecular weight compound PKF050-638 (Daelemans et al.,
2002) arrests transcription of HIV-1, inhibits the production of
new virions and reduces HIV-1 levels (Urcuqui-Inchima et al.,
2011; Perwitasari et al., 2014).
Human T-Cell Leukemia Virus Type-1
(HTLV-1)
Belonging to the genus Deltaretrovirus of the Retroviridae
family, HTLV-1 causes adult T-cell leukemia, HTLV-1 associated
myelopathy/tropical spastic paraparesis and HTLV-1 uveitis.
After HTLV-1 entry, the viral genomic RNA is reverse-
transcribed and integrated into the host genome. HTLV-1
genomic RNA encodes more than 10 viral proteins and has three
alternatively-spliced forms of viral mRNAs that are unspliced
(encodes Gag, Pro, and Pol proteins), singly (partially)-spliced
(encodes Env) and doubly (fully)-spliced (encodes accessory
proteins, such as Tax, Rex, P30II, p12, and p13). The viral
mRNA from the provirus for the first round of transcription
is completely spliced to tax/rex mRNA by the cellular splicing
machinery. Tax stimulates gradual accumulation of Rex in the
nucleus which in turn permits Rex-mediated nuclear export of
unspliced and partially spliced viral RNA into the cytoplasm
(Younis and Green, 2005; Knipe and Howley, 2013; Nakano and
Watanabe, 2016).
Similar to the HIV-1 Rev protein, HTLV-1 Rex protein
recognizes the Rex Responsive Element (RxRE) on the mRNAs
to form a Rex-viral mRNA complex for selective nuclear-export
using CRM1 (Table 1) (Nakano andWatanabe, 2016). Unlike the
RRE in HIV-1 mRNAs, RxRE is in all HTLV-1 mRNAs but they
differ in nuclear export efficiency by Rex (Nakano andWatanabe,
2016). Rex is indispensable for efficient viral replication, infection
and spread since it is considered to regulate the switch between
the latent and productive phases of the HTLV lifecycle (Younis
and Green, 2005). Without a functional Rex, viral structural and
enzymatic post-transcriptional gene expressionwould be severely
repressed and lead to non-productive viral replication (Younis
and Green, 2005).
Influenza
The family Orthomyxoviridae consists of negative sense, single-
stranded, segmented RNA viruses, influenza being the prototypic
virus. The replication cycle of orthomyxoviruses consist of
attachment, receptor-mediated endocytosis followed by release
of the viral ribonucleoprotein (vRNP) in the cytoplasm. The
vRNP is then imported into the nucleus where it undergoes
transcription and replication. The newly formed vRNPs are
exported to the plasma membrane to complete assembly of
viral particles and budding (Knipe and Howley, 2013) The
RNA genome of influenza virus encodes 11 viral proteins.
The transmembrane proteins hemagglutinin, neuraminidase and
M2 protein on the viral envelope assist in attachment and
penetration, as well as M2 protein-mediated release of the vRNP
into the cytoplasm. The vRNP consists of the (−)ssRNA, three
polymerase proteins (PB1, PB2, and PBA) that form the viral
RNA polymerase complex (3P) and nucleoprotein (NP). Nuclear
import of the vRNP is facilitated using importin-α (Imp-α).
Following transcription and replication in the nucleus, newly
synthesized RNA is complexed with NP to form new vRNPs;
reviewed in Nayak et al. (2004) and Boulo et al. (2007).
Transport of the vRNP into the cytoplasm is coordinated by
the NES-containing viral nuclear export protein (NEP). NEP,
formally called NS2, utilizes the CRM1-mediated nuclear export
pathway to transport the viral core to the assembly site at the
plasma membrane (Table 1; Elton et al., 2001; Boulo et al.,
2007; Perwitasari et al., 2014). This is a critical step for the
formation of mature viral particles and is conserved in influenza
A, B and C strains (Paragas et al., 2001; Paterson and Fodor,
2012). In addition to NEP, the viral matrix protein (M1) and
NP also play important roles in this step. Absence of either
protein results in retention of vRNPs in the nucleus (Bui et al.,
2000; Neumann et al., 2000). CRM1 silencing resulted in reduced
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viral replication, lung viral load and proinflammatory cytokine
expression (Watanabe et al., 2001; Perwitasari et al., 2014).
Respiratory Syncytial Virus (RSV)
Reclassified under the newly formed Pneumoviridae family,
formerly under Paramyxoviridae, RSV is the major causative
agent of lower respiratory tract infections among infants,
immunocompromised and elderly with no approved antiviral
therapy or vaccines (Simoes et al., 2015; Afonso et al., 2016).
RSV consists of a nucleocapsid core, wherein the RNA genome
is tightly encapsulated by nucleocapsid proteins and the viral
polymerase complex, contained within a lipid bilayer envelope.
RSV infection is initiated when the large glycoprotein G facilitates
attachment of the virion to the host membrane followed by
fusion of the viral envelope with the host membrane mediated
by the viral F protein. The nucleocapsid core is then released
into the cytoplasm where the virus-encoded polymerase complex
formed by L and P proteins, direct the transcription of the
(−)ssRNA genome to generate the primary mRNA transcripts,
which are then translated into viral proteins (Ghildyal et al., 2006,
2009). The Matrix (M) protein possesses both NLS and NES
sequences that enable it to shuttle in and out of the nucleus in
the early and late stages of infection using importin β (Imp-β)
and CRM1, respectively. At the early stages of viral replication
[about 5–6 h post infection (h.p.i)], the newly-synthesized M
protein translocates into the nucleus via the action of the nuclear
transport protein Imp-β and accumulates in the nucleus up to 16
h.p.i (Ghildyal et al., 2006, 2009; Bajorek et al., 2014).
Specific inhibition of CRM1-mediated nuclear export by
LMB increased nuclear accumulation of M protein and reduced
virus production (Table 1). In addition, mutations in the CRM1
recognition site prevented successful nuclear export ofM protein,
which eventually halted virus production due to the failure of M
protein to localize at the assembly sites. This shows that timely
CRM1-dependent nuclear export of M protein is central to RSV
infection (Ghildyal et al., 2006, 2009, 2012; Bajorek et al., 2014).
Dengue Virus
Dengue viruses are the major causative agents of arthropod-
borne viral diseases, such as dengue fever and dengue
hemorrhagic fever. A member of the Flaviviridae family,
the dengue virus (+)ssRNA genome encodes ten viral
proteins including three structural proteins (capsid, pre-
membrane/membrane, and envelope) and seven non-structural
(NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5) proteins (Knipe
and Howley, 2013).
Following adsorption, the virus is internalized via receptor-
mediated endocytosis. The acidic pH of the endosome promotes
fusion of the viral endosomal membranes and allow the release
and uncoating of the viral nucleocapsid into the cytoplasm.
The RNA genome is then translated and replicated in the
cytoplasm. Viral assembly is conducted at the endoplasmic
reticulum following several rounds of translation followed by
maturation of the virion in the Golgi apparatus; reviewed in
Clyde et al. (2006) and Knipe and Howley (2013).
The NS5 protein is the largest and highly conserved among
dengue NS proteins. It localizes both in the cytoplasm and
nucleus. The N terminal domain of NS5 carries out two
biochemically distinct methylation reactions for RNA capping
and the C terminal domain has an RNA-dependent RNA
polymerase activity required for synthesis of the viral genome
in the cytoplasm; reviewed in Lim et al. (2015). DENV-2 NS5
possesses two NLSs that are capable of binding Imp-α/β and
Imp-β, respectively (Pryor et al., 2007). It also carries an NES
sequence that interacts with CRM1 (Table 1; Pryor et al., 2006).
The bidirectional transport of NS5 has been shown to be critical
for modulation of host antiviral responses, particularly IL-8
induction, and viral replication. Inhibition of CRM1 in dengue
virus type-2 infections resulted in nuclear accumulation of NS5,
reduced IL-8 induction and altered viral replication kinetics
(Pryor et al., 2006; Rawlinson et al., 2009).
Rabies Virus
Rhabdoviridae consist of a morphologically distinct group of
enveloped ss(−)RNA viruses with an elongated rod-like or bullet-
like shape. Rabies virus ss(−)RNA genome encodes five viral
proteins and replicates entirely in the host cell cytoplasm. The
nucleoprotein (N), the large protein (L) and the phosphoprotein
(P) enclose the genome to form the virion core that is
further enclosed by the matrix (M) protein followed by a viral
envelope embedded with glycoprotein (G). L and P form an
RNA-dependent RNA polymerase complex and are involved in
viral transcription and replication. The rabies virus P protein
also acts as a regulatory protein that antagonizes interferon-
mediated antiviral responses of the host cell (Knipe and Howley,
2013).
The P protein is expressed as five isoforms P1 to P5. The
nucleocytoplasmic localization of these P isoforms is dependent
on the activity of the NES and NLS sequences located at the
N- and C-terminals, respectively. P1 and P2 carry the dominant
CRM1-dependent NES while P3–P5 carry a truncated version
of NES allowing NLS to become the primary localization signal.
This results in P1 and P2 being localized in the cytoplasm while
P3–P5 are nuclear. (Table 1; Pasdeloup et al., 2005; Oksayan et al.,
2012). NES of P protein is conserved throughout the Lyssavirus
genus (Pasdeloup et al., 2005). P protein-mediated antagonism of
interferon production in the host cell has been shown to play a
major role in neuroinvasion and infection of peripheral nerves as
it is essential for stable viral replication (Yamaoka et al., 2013). In
normal cells, the phosphorylation of STAT1 enables it to localize
in the nucleus and regulate gene expression. P protein inhibits the
phosphorylation, nuclear translocation andDNAbinding activity
of STAT1 resulting in inhibition of both type I and II interferon
responses (Vidy et al., 2007). In addition, P protein interferes with
the phosphorylation of interferon regulatory factor 3 (IRF-3)
to retard interferon production (Brzozka et al., 2005). Thus, P
protein interaction is critical to rabies pathogenicity. Interplay
between theNLS andNES sequences on P protein in combination
with the phosphorylation and dephosphorylation of the signal
peptides regulate the localization of the viral protein (Gupta
et al., 2000; Pasdeloup et al., 2005). The complex interaction of
P protein with the host cell trafficking machinery ensures success
of infection and suppression of host antiviral responses (Oksayan
et al., 2012).
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Human Cytomegalovirus (HCMV)
Herpesviruses are highly disseminated in nature with hosts
ranging from bivalves to humans. Named after their
characteristic icosahedral architecture, a typical herpesvirus
consists of an outer envelope, tegument or matrix layers, and
a capsid enclosed dsDNA genome (Knipe and Howley, 2013).
Human cytomegalovirus, the largest member of the herpesvirus
family, is the most significant cause of congenital disease. The
virion is composed of a glycoprotein embedded host-derived
envelope that encloses the tegument layer and the viral core
composed of the icosahedral protein capsid and a dsDNA
genome. Viral gene expression takes place in three stages:
immediate-early, early and late stages. The tegument (or matrix)
layer, lies beneath the envelope and above the viral capsid, is
composed of nearly 32 proteins that conduct a range of functions
including host cell response and orchestrating viral assembly.
These matrix proteins are added to the nucleocapsid partly in
the nucleus and partly in the cytoplasm during viral maturation.
In the early stages of infection, tegument proteins associate with
microtubules and the NPC to deliver the viral genome into the
nucleus. In the final stages of infection these proteins coordinate
stabilization of the nucleocapsid, trafficking from the nucleus,
assembly at the plasma membrane and budding (Kalejta, 2008;
Knipe and Howley, 2013).
Many tegument proteins are conserved across herpesviruses
and are highly immunogenic. The lower matrix protein
phosphoprotein 65 (pp65) is the most abundant tegument
protein and a prominent target for MHC class I–restricted CD8
and MHC class II CD4 T-cell responses (Frankenberg et al.,
2012; Knipe and Howley, 2013). Pp65 localizes in the nucleus
immediately after viral entry and carries out immune evasion
tactics. Pp65 acts on two fronts, on one side it phosphorylates
the viral immediate-early proteins and thereby protects them
from being recognized by the host immune system (Gilbert et al.,
1996). Pp65 also retards the expression of both MHC class 1 and
II molecules thus crippling viral recognition by both CD4+ and
CD8+ T cells (Odeberg et al., 2003; Frankenberg et al., 2012).
Pp65 also retards the host interferon response, particularly type
1 interferon response, reducing expression of interferon beta
and other cytokines (Abate et al., 2004). Disruption of CRM1-
medited export of pp65 resulted in its nuclear retention and
decreased viral replication (Sanchez et al., 2007). During the lytic
stage of the viral cycle, pp65 utilizes CRM1-mediated transport
to shuttle into the cytoplasm (Table 1; Sanchez et al., 2007;
Frankenberg et al., 2012). Another key function of pp65 is to
inhibit natural killer cell cytotoxicity by directly binding to the
activation receptor NKp30 (Arnon et al., 2005).
Another tegument protein UL94 is a late protein carrying both
NLS and CRM1-dependent NES sequences. Mutation in these
sequences disrupted its intracellular localization and upset its
shuttling function (Liu et al., 2012). Other tegument proteins
play crucial roles during infection including transcription
of the genome (pp71, ppUL35, ppUL69, UL47, and UL48),
translocation of maturing nucleocapsids from the nucleus to the
cytoplasm (pp150 and pp28), modifying host cell response to
infection (pIRS1/pTRS1), interfering with host cell cycle (pp71,
ppUL69, and UL97) and optimize the nuclear environment for
viral replication; reviewed in Kalejta (2008) and Knipe and
Howley (2013).
LEPTOMYCIN B AND SYNTHETIC
INHIBITORS
Inhibition of nucleocytoplasmic transport by natural and
synthetic products has been pursued as a therapeutic avenue in
cancer based on a number of biologic observations (Niu et al.,
2015). Several small molecule inhibitors of CRM1 have been
developed and tested against a variety of neoplasms, primarily in
vitro. These targeted therapies work, at least in part, by forcing
nuclear accumulation of tumor suppressor proteins that are
mislocalized or expressed at abnormal levels in cancer cells, to
initiate cascades of apoptosis (Niu et al., 2015). The successful
application of CRM1 inhibitors against cancer gives support to
their potential as antiviral agents.
Leptomycin B: The Prototypical CRM1
Inhibitor
Leptomycin B (LMB; also known as elactocin, mantuamycin,
and NSC 364372) is a polyketide isolated from Streptomyces and
the first specific inhibitor of CRM1 to be discovered (Mutka
et al., 2009; Turner et al., 2012a). It rapidly induces cytotoxic
effects in cancer cell lines via covalent inhibition of CRM1
(IC50 value 0.1–10 nM) (Mutka et al., 2009). Its nanomolar
potency stems from a highly specific binding to Cys528 via
a Michael-type addition and subsequent inhibition of CRM1-
mediated export from the nucleus (Kudo et al., 1998, 1999).
Its clinical development was discontinued midst a single phase
1 trial in mouse tumor models due to significant toxicity
(anorexia and malaise) without apparent efficacy (Newlands
et al., 1996).
Mechanism of Action
Leptomycin B (LMB) is chemically defined as 19-[(2S,3S)-3,6-
dihydro-3-methyl-6-oxo-2H-pyran-2-yl]-17-ethyl-6-hydroxy-
3,5S,7S,9R,11,15R,hexamethyl-8-oxo-2E,10E,12E,16Z,18E-
nonadecapentaenoic acid. It is a polyketide with a
α,β-unsaturated d-lactone portion that covalently binds
through Michael addition to the Cys528 in the CRM1 NES
groove (or Cys529 in Saccharomyces pombe). Binding with LMB
initially forces CRM1 to remain in a half open conformation.
This is followed by hydrolysis of the lactone group of LMB in
the presence of basic amino acid residues in the NES groove and
thereby stabilizes the interaction making it irreversibly bound to
CRM1 (Figure 3; Kudo et al., 1998). The persistent shutdown
of CRM1 mediated nuclear export and off target activity are
possibly the reasons why it is highly deleterious to the cell
(Newlands et al., 1996; Fung and Chook, 2014; Perwitasari et al.,
2014). LMB has been shown to block the export of influenza viral
ribonucleoproteins (vRNP) containing the (−)ssRNA genome,
nucleoprotein and polymerases, from the nucleus into the
cytoplasm and thereby inhibit influenza replication (Perwitasari
et al., 2014). Table 1 lists some of the outcomes of LMB treatment
in cells infected with selected viruses.
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FIGURE 3 | CRM1-inhibition by Leptomycin B. Leptomycin B binds to CRM1 at Cys528 residing in its NES-binding groove and inhibits the binding of the cargo to
CRM1.
Side Effects
Leptomycin B (LMB) binds covalently to Cys528 located in the
NES-binding groove of CRM1, inactivates it in an irreversible
manner. Hence, LMB is highly toxic and in vivo application is
not justified (London et al., 2014). However, LMB alternatives
ratjadone and anguinomycin A inhibit CRM1-mediated export
almost identically, binding covalently to Cys528 with reduced
cytotoxicity (Sun et al., 2013). This suggests that we can
design/utilize synthetic and/or natural compounds inhibiting
CRM1 in the same mechanism of action as LMB but with no or
reduced cytotoxicity.
Synthetic CRM1 Inhibitors
Nuclear Export Inhibitors (NEIs)-KOS 2464
Mutka et al. have synthesized analogs of LMB with substantially
improved therapeutic windows while maintaining the high
potency of LMB. They had better in vivo tolerance, up to 16-folds
higher than LMB (Table 2). Although the NEIs cause inhibition
of CRM1 in normal and tumor cell types, the downstream
consequences of this inhibition are different to that of LMB,
inducing cell cycle arrest (instead of apoptosis) in normal lung
fibroblasts and apoptosis in p53 wild-type cancer models (HCT-
116 colon model and SiHa cervical cancer) (Mutka et al.,
2009). Topoisomerase IIα (topo IIα) is a transcription factor
that activates DNA-cleavable complexes and induces cell death.
However, drug resistant myeloma cells mislocalize topo IIα to
the cytoplasm using CRM1 nuclear export to escape apoptosis
(Engel et al., 2004). KOS-2464 (Kosan Biosciences/Bristol-Myers
Squibb), a semisynthetic NEI induces rapid and prolonged
inhibition of CRM1, and apoptosis in drug resistant multiple
myeloma cell lines at nanomolar concentrations (low IC50 value
of 2 nM) without the toxicity associated with LMB (Turner et al.,
2012b). Treated cells were found sensitive to topo IIα inhibitors
while normal cells remained unaffected by the combined effects
of CRM1 and topoIIα inhibition (Turner et al., 2009). In
comparison to LMB, the absence of apoptosis despite cell cycle
arrest by KOS2464 in normal lung fibroblasts is indicative of
reduced off-target activity (Turner et al., 2012a).
N-Azolylacrylate Analogs
An N-azolylacrylate analog, PKF050-638 (Table 2) developed
by Daelemans et al. was found to inhibit the nuclear export
of HIV-1 Rev protein, a crucial factor for viral infection
(as discussed in the previous section). PKF050-638 reversibly
disrupts CRM1-NES interaction, targeting Cys539 in a dose-
dependent manner at micromolar concentrations. PKF050-638
displayed high selectivity in binding to CRM1 while its trans-
enantiomer (PKF050-637) was ineffective (Daelemans et al.,
2002).
CBS9106
CBS9106 (Table 2) was found to reversibly inhibit CRM1-
mediated export both in vivo and in vitro. A cell cycle phenotype-
based protocol was used to determine its anti-tumor activity
against various cancer cell lines including multiple myeloma
and showed varied cytotoxicity depending on the cell line (IC50
ranging between 3 and 278 nM). The compound induced cell
cycle arrest and apoptosis in cancer cells in a time- and dose-
dependent manner in both in vivo and in vitro models. In
multiple myeloma cells, reduced NF-κB activity due to CRM1-
inhibition was found to be a key factor for the inhibitory effects
of CBS9106 (Sakakibara et al., 2011). A commercially cost-
effective derivative of CBS9106 designated S109 was also shown
to reversibly inhibit CRM1-meidated nuclear export in renal
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cancer cells and reduce proliferation and colony formation. S109
down regulated the expression of cyclinD1, a nuclear protein that
drives the G1 to S phase transition in the cell cycle, and induced
the expression and accumulation of p53, p21, p27, and FOXO1.
This resulted in cell cycle arrest at G1 phase in renal cancer cell
lines (Liu et al., 2016).
Both CBS9106 and S109 were found to exert CRM1
inhibition similar to LMB. However, unlike LMB they induced
a reduction in CRM1 protein levels without affecting CRM1
mRNA expression. CBS9106 is shown to induce proteasome-
dependent CRM1 protein degradation since treatment with
bortezomib counteracted this effect (Saito et al., 2014). S109 is
also likely to have the same mechanism (Liu et al., 2016).
Selective Inhibitors of Nuclear Export (SINE)
SINEs are first-in-class, novel selective inhibitors of nuclear
export (KPT-SINE) developed by Karyopharm pharmaceuticals,
USA using Concensus Induced Fit Docking (cFID). SINEs
are designed such that they bind to CRM1 covalently, similar
to LMB, but reversibly (Fung and Chook, 2014; Perwitasari
et al., 2014). KPT-SINE compounds are orally bioavailable
compounds developed as chemotherapeutics for various solid
and hematologic malignancies (Turner and Sullivan, 2008;
Turner et al., 2014; Sun et al., 2016). By exporting them from
the nucleus of normal cells, CRM1 prevents multiple tumor
suppressor proteins from acting in the absence of DNA damage
or other oncogenic insults; thus, SINE compounds force the
nuclear retention, accumulation, and functional activation of
tumor suppressor proteins to limit oncogenesis (Perwitasari et al.,
2014).
The administration of KPT compounds to animals is
significantly less toxic than LMB (Fung and Chook, 2014). Two
KPT SINE inhibitors (KPT 330 or Selinexor and KPT 335 or
Verdinexor) are now in Phase 1/2 clinical trial for solid and
hematological cancers (www.clinicaltrails.gov). SINE-mediated
CRM1 inhibition enables nuclear retention of tumor suppressor
proteins and anti-apoptotic signals (IκB, Survivin, p53, NPMc
mutant, p27, and FOXO) and lead to cell cycle arrest and
apoptosis in cancerous cells (Parikh et al., 2014; Das et al., 2015).
SINEs are slow-reversible inhibitors of CRM1
SINEs are typically 350 Da compounds, in comparison to
540Da LMB, sharing a phenyl triazole scaffold with different
Michael addition acceptor side chains. The smaller structure
of SINEs in comparison to LMB (Table 2) translates as 40%
occupancy of the NES groove leaving the remaining portion of
the hydrophobic groove open and unoccupied. SINEs bind to
CRM1 with their trifluoromethyl groups buried deep within the
NES binding groove. Unlike LMB, SINEs are not hydrolyzed after
conjugation probably due to its attachment deep into the NES
groove protected from potential nucleophiles and oxyanions. The
conjugation of KPT 185 to CRM1 and its inhibition activity
is reversed by 40–60% after 24 h most likely due to a lack of
the hydrolysis of its active enone group. The slow reversibility
of SINEs possibly contributes to their improved tolerance since
withdrawal of the drug allows deconjugation of the drug from
CRM1 and essential nuclear export to resume in normal cells.
They bind long enough to kill cancer cells but their reversible
nature allows then to be released in time to spare normal cells
(Sun et al., 2013; Fung and Chook, 2014; Dickmanns et al.,
2015).
OTHER NATURALLY OCCURRING
INHIBITORS
Several small molecules found in nature have CRM1 inhibitor
activity; several such molecules are already in use in mainstream
and/or complementary medicine with bioavailability and in vivo
safety data already in hand. These present an attractive group of
drugs for development of antiviral strategies.
Antiviral activities have been reported for numerous
medicinal plants and have been extensively used as part of
traditional medicine globally for centuries. Herbal products
with confirmed clinical safety features are attractive starting
material for the identification of new antiviral activities.
Recent demonstration of anti-HIV-1 activity of extracts of
Pelargonium sidoides, licensed in Germany as the herbal
medicine Umckaloabo R© suggests that investigation of antiviral
activities among herbal extracts holds immense potential (Niu
et al., 2013, 2015; Forouzanfar et al., 2014; Helfer et al., 2014;
Liu X. et al., 2014; Wang et al., 2015). A selection of naturally
occurring CRM1 inhibitors are described below.
FOXO Family Export Inhibitors
FOXO or Forkhead family of transcription factors (FOXO1a,
FOXO3a, and FOXO4) are activated in response to tumor
suppressors, such as PTEN lipid phosphatase to retard cell
growth and induce apoptosis (Nakamura et al., 2000). Defective
PTEN expression and/or CRM1 overexpression results in
mislocalization of FOXO to the cytoplasm and promotes
tumorigenesis (Ramaswamy et al., 1999; Brunet et al., 2002).
In search for FOXO inhibitors Kau et al. (2003) utilized a cell-
based, chemical genetic screening regimen to screen compounds
from the NCI Structural Diversity Set, ChemBridge DiverSetE,
and a small collection of NCI marine extracts to detect nuclear
localization of FOXO. 11 compounds were found to interrupt
CRM1-mediated nuclear export targeting Cys528. Eight of these
compounds had an α,β-unsaturated ketone or amide group
capable of Michael-type addition with Cys528 and the other 3
compounds probably modified Cys528 through a nucleophilic
attack or induced a chemical rearrangement (Kau et al., 2003)
Valtrate, Acetoxychavicol Acetate, and
Prenylcoumarin Osthol
These are small molecule inhibitors of CRM1 isolated from
Valerianae fauriei, Alpinia galangal, and Cnidii Monnieris
Fructus, respectively (Table 2). All three compounds were shown
to disrupt CRM1-mediated export of HIV-1 Rev protein. Valtrate
and acetoxychavicol acetate have also been shown to inhibit
nuclear export of influenza viral RNP (Watanabe et al., 2001,
2011). Their mechanism of action was demonstrated to be the
same as LMB (Murakami et al., 2002; Tamura et al., 2010a,b).
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Ratjadone Analogs
Ratjadone analogs A, B, C, and D isolated from a myxobacterium
Sorangium cellulosum (Table 2), are CRM1 inhibitors that have
anticancer and antifungal properties. Being similar in structure
to LMB, ratjadones use the same molecular mechanism to inhibit
CRM1 (Koster et al., 2003; Meissner et al., 2004). Drug resistant-
human multiple myeloma cell lines became more sensitized after
inhibition of CRM1-meidated nuclear export using ratjadone.
They were more responsive to topoIIα inhibitors (such as
doxorubicin and epoposide) and to anticancer drugs, such
as topotectan (a topoisomerase inhibitor) and cis-platinum (a
DNA cross linking agent) (Turner et al., 2009). Treatment with
ratjadones has shown to inhibit cell proliferation by inducing cell
cycle arrest at G1 and an increase in size of the nuclei (indicative
of effective block of nuclear export) (Burzlaff et al., 2003; Koster
et al., 2003). Recently ratjadone A has been shown to exert anti-
HIV activity in vitro in a dose-dependent manner at nanomolar
concentrations. Its inhibitory effect occurs 12 h.p.i. and interferes
with the formation of the CRM1-Rev-NES complex by binding
to CRM1 but not to Rev (Fleta-Soriano et al., 2014).
Goniothalamin and Anguinomycin
A styryl lactone isolated from Goniothalamus (Annonaceae),
goniothalamin (Table 2) has a broad range of pharmacological
properties including antimicrobial and anti-tumorigenic activity
(Mosaddik and Haque, 2003; Seyed et al., 2014). Goniothalamin
has been reported to induce cell cycle arrest at the G2/M phase
and apoptosis in breast cancer cells with IC50 value of 1.46 µM
(Chen et al., 2005). The compound was shown to inhibit CRM1-
mediated nuclear export at 1 µM using the same mechanism as
LMB (Wach et al., 2010).
Anguinomycin isolated as a natural product from
Streptomyces spec. and produced by total chemical synthesis
synthetized have been reported to shutdown CRM1-mediated
nuclear protein export at concentrations above 10 nM
(Dickmanns et al., 2015). Its α,β-unsaturated lactone group
interacts with CRM1 in a similar mechanism to LMB (Bonazzi
et al., 2010).
Piperlongumine
Piperlongumine (5,6-dihydro-1-[(2E)-1-oxo-3-(3,4,5-trime
thoxyphenyl)-2-propenyl]-2(1H)-pyridinone) is a natural
alkaloid of the Long pepper (Piper longum L. – Piperaceae)
widely used in Indian and Chinese traditional medicine
(Table 2). Piperlongumine exhibits multiple biological and
pharmacological activities including antimicrobial, anti-
inflammatory, platelet aggregation inhibitor and antitumor
activities; reviewed in Bezerra et al. (2013). The electrophilic
α,β-unsaturated carbonyl group of piperlongumine has been
shown to covalently modify Cys528 of CRM1 in a Michael
addition manner and inactivate CRM1-mediated protein export
(Niu et al., 2015). This suggests piperlongumine-induced
suppression of constitutive NFκB, Akt/mammalian target of
rapamycin (mTOR) and MAPK signal pathways and cytotoxicity
in tumorigenic cells demonstrated in several studies could
be explained by its interference with CRM1-mediated export
(Ginzburg et al., 2014; Shrivastava et al., 2014; Liu Q. R. et al.,
2014). Piperlongumine was demonstrated to inhibit CRM1-
mediated nuclear export in HeLa cells after 24 h-exposure
with an IC50 value of 16.3 µM, showing cellular tolerance and
potential for oral administration (Niu et al., 2015).
Plumbagin
Plumbagin, a natural bicyclic naphthoquinone (Table 2)
derived from Plumbago zeylanica, is known to have
antimicrobial, anticancer, antiproliferative, chemopreventive,
chemotherapeutic, and radiosensitising properties (Ahmad et al.,
2008; Aziz et al., 2008; Sinha et al., 2013). It is known to induce
apoptosis and cell cycle arrest by suppressing constitutive the
NF-kB signal pathway (Ahmad et al., 2008). Plumbagin has
been demonstrated to interfere with CRM1-mediated export,
directly interacting with the transporter protein same as LMB
which could explain some of its therapeutic properties (Liu
X. et al., 2014). Plumbagin disrupts CRM1 export and retains
tumor suppressors, such as FOXO1, p21, p53, and p73 in the
nucleus suggesting this as a mechanism for the naphthoquinone’s
antitumorigenic effects (Liu X. et al., 2014).
Curcumin
Curcumin (Diferuloylmethane) is the major constituent of
Curcuma longa (Table 2), an ancient spice widely used in
Indian traditional medicine. Extensive research has showed
curcumin as the major bioactive chemical responsible for a wide
array of pharmacological properties that involve regulation of
various cellular growth and transcription, cytokines production
or inhibition, protein kinases, and other enzymes (reviewed in
Aggarwal et al., 2007; Jagetia and Aggarwal, 2007). Suppression
of constitutive NF-kB signal pathway (Aggarwal and Shishodia,
2004), myeloid differentiation protein 2 (MD-2) (Gradisar et al.,
2007), Akt/ mTOR (Beevers et al., 2009), and STAT3 signaling
(Kim et al., 2003) have been suggested for the antitumorigenic
effects of curcumin. Recently, CRM1 has been confirmed as
one of the cellular targets directly interacting with curcumin.
Curcumin was shown to covalently interact with CRM1 at
Cys528, induce the nuclear retention of FOXO1 and upregulates
the expression of p73 and p27 in HeLa cells. In addition,
CRM1 modulation by curcumin downregulated the expression
of proinflammatory proteins COX-2 and cyclin D1 in a dose-
dependent manner (Niu et al., 2013).
15-Deoxy-Prostaglandin J2(15d-PGJ2)
Prostaglandins (PGs) are signaling molecules involved
in inflammation, hemostasis, gastrointestinal secretion,
thrombosis, and other cellular functions. 15d-PGJ2 is a
member of the prostaglandin (PG) J(2) family and has both
anti- and pro-inflammatory properties. At low concentrations,
endogenous 15d-PGJ2 exerts anti-inflammatory effects,
promoting chemotaxis and activation of eosinophils, while
at high concentrations it induces eosinophil apoptosis in a
PPARγ-independent manner (Miwa et al., 2004; Ueki et al.,
2007). Exogenous administration of 15d-PGJ2 has shown to
have antiviral, antiproliferative and anti-inflammatory effects.
15d-PGJ2 promotes translocation of PPARγ to the nucleus
and activation of NFκB/IκB signaling pathway to mediate
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anti-inflammatory responses. Exogenous 15d-PGJ2 (Table 2)
has been shown to interrupt CRM1-mediated nuclear export by
interacting with CRM1 similar to LMB (Hilliard et al., 2010).
In comparison to LMB higher concentrations of 15d-PGJ2 are
required to inhibit CRM1 probably because its α,β-unsaturated
carbonyl group can only modify selected or exposed nucleophilic
groups. However, this also enables targeted inhibition of a
subset of proteins. 15d-PGJ2 and/or derivatives of this PG as a
CRM1 inhibitor hold promise as therapeutic agents as it can be
produced by higher eukaryotes and can therefore function as
both endogenous and exogenous regulator of CRM1 mediated
nuclear export (Hilliard et al., 2010).
POTENTIAL NATURAL CRM1 INHIBITORS
In addition to the above listed natural CRM1 inhibitors,
several natural compounds have been demonstrated to inhibit
viruses, interfering with the nuclear export of viral components,
both protein and RNA. The similarity between the effect
of LMB and some natural compounds present in traditional
medicines suggest that they are CRM1-inhibitors. For instance,
thymoquinone, the main constituent of the volatile oil from
Nigella sativa (black cumin) seeds, is reported to protect
laboratory animals against chemical toxicity and induction of
carcinogenesis. Thymoquinone reacts in vitro with glutathione
through a spontaneous and rapid reaction that produces
a dihydrothymoquinone-thioether via 1,4-Michael addition
mechanism, like LMB, thereby suggesting that thymoquinone
may be capable of inhibiting CRM1 (Forouzanfar et al., 2014).
A lignan glycoside isolated from the latex of Calotropis
gigantea (Asclepiadaceae), (+)-pinoresinol 4-O-[6′′-O-
vanilloyl]-β-d-glucopyranoside, has been shown to exert
anti-influenza activity at the early stage of viral replication in
both influenza A [A/PR/8/34 (H1N1), A/FM/1/47 (H1N1), and
A/Aichi/2/68 (H3N2)] and influenza B (B/Lee/1940) subtypes.
The lignan glycoside efficiently inhibited the virus-induced
translocation of NF-κB and the activation of the NF-κB pathway
in a dose-dependent manner (IC50 from 13.4 to 39.8 µM). The
extract also reduced nuclear export of viral ribonucleoproteins,
suggesting the involvement of CRM1 interaction (Parhira et al.,
2014).
Clemastanin B, a lignan isolated from Isatis indigotica
root, inhibits human [H1N1, H3N2, and influenza B
(B/Guangzhou/GIRD08/09)] and avian influenza viruses
(H6N2, H7N3, and H9N2) with IC50 ranging from 0.087 to
0.72 mg/ml. The anti-influenza compound was found to reduce
viral titer in in infected MDCK cells at early stages of infection.
Although the mechanism of action has not been elucidated,
nuclear retention of viral ribonucleoproteins in the treated cells
suggests clemastanin B targets viral endocytosis, uncoating or
RNP export from the nucleus to exert its effects (Yang et al.,
2013).
Licorice (Glycyrrhiza uralensis Fisch.) is a common herb
used in traditional Chinese medicine for airway symptoms that
have been proved to have anti-RSV activity (Chang et al.,
2011, 2012; Wang et al., 2011). These prescriptions have been
shown to exert antiviral properties by stimulating anti-viral
cytokines, such as interferon-β and TNF-α in both upper (Hep-
2) and lower (A549) respiratory epithelial cell lines (Feng
Yeh et al., 2013). Glycyrrhizin (GL), 18β-glycyrrhetinic acid
(GA), liquiritigenin (LTG), licochalcone A (LCA), licochalcone
E (LCE), and glabridin (GLD) are the main active components
in licorice extracts which possess antiviral and antimicrobial
activities (Wang et al., 2015). GL and GA have been shown to
inhibit replication of rotavirus, RSV, HIV etc. by inhibiting virus
replication, preventing viral attachment or enhancing host cell
activity. But their mechanism of action is yet to be investigated
(Wang et al., 2015).
CONCLUSION AND FUTURE PROSPECTS
Regulated, appropriate translocation and subcellular localization
of proteins is essential for regulation of replication, transcription
and translation. Dysregulation of this system is observed
in several pathological conditions including cancer and
viral infections. Shuttling transport receptors mediate all
cargo transport across the nuclear pore complex via similar
mechanisms, ensuring regulated localization of transcription and
growth factors, cytokines and other proteins/mRNA. CRM1 is a
conserved and well characterized nuclear exporter that binds to
protein/mRNA cargoes tagged with an NES motif. It is the sole
exporter for several oncogenes and tumor suppressor proteins
and is involved in regulating cell cycle, ribosome biogenesis and
maintenance of chromosomal and nuclear structures.
Overexpression of CRM1 is observed in solid and hematologic
malignancies. Mislocalization of regulatory factors away from
their original site of action in the nucleus promotes malignancy,
evasion of apoptosis and detection, and drug resistance. CRM1-
mediated export is also co-opted by viruses belonging to
diverse families at various stages of their replication to mediate
infection and retard host antiviral responses. Disruption of
CRM1-mediated nuclear export in both cancer and viral
infections resulted in increased response to therapeutic agents
and successful elimination of abnormal/infected cells.
Several small molecule inhibitors of CRM1 have been
developed and tested against a variety of neoplastic cells and
viral infected cell lines, primarily in vitro. LMB, the first and
prototypical inhibitor, targets Cys528 of CRM1, altering its three-
dimensional structure and capacity to transport cargo across
the NPC. The high cytotoxicity of LMB makes it unsuitable for
therapeutic purposes; however it initiated the search for synthetic
and natural alternatives capable of eliciting the same effects
without the cytotoxicity.
Synthetic CRM1 inhibitors, such as KOS2464, CBS9106,
N-azoylacrylate analogs, and SINEs have proven capable of
interrupting tumorigenesis in both solid and hematological
malignancies. However, synthetic drugs present the risk of
unwanted side effects and development of resistance in both
cancer and viruses. Numerous medicinal plants have been
extensively used as part of traditional medicine globally for
centuries, several of these have been shown to have CRM1
inhibiting activity and exert antiviral properties. These present
an attractive group of drugs for development of antiviral
strategies since they are already in use in mainstream and/or
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complementary medicine with bioavailability and in vivo
safety data already in hand; importantly, these compounds
have relatively low cytotoxicity compared to synthetic CRM1
inhibitors.
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